Schliess Freimut, Heise Tim, Benesch Carsten, Mianowska Beata, Stegbauer Constance, Broge Björn, Gillard Pieter, Binkley George, Crône Véronique, Carlier Sébastien, Delval Cécile, Petkov Anton, Beck Jan-Philipp, Lodwig Volker, Gurdala Mikolaj, Szecsenyi Joachim, Rosenmöller Magda, Cypryk Katarzyna, Mathieu Chantal, Renard Eric, Heinemann Lutz
1 Profil, Neuss, Germany.
2 Department of Pediatrics, Oncology, Hematology and Diabetology Łódź, Medical University of Łódź, Poland.
J Diabetes Sci Technol. 2019 Mar;13(2):261-267. doi: 10.1177/1932296818803588. Epub 2018 Sep 21.
In the last 10 years tremendous progress has been made in the development of artificial pancreas (AP) systems for people with type 1 diabetes (T1D). The pan-European consortium CLOSE (Automated Glu cose Contro l at H ome for People with Chronic Disea se) is aiming to develop integrated AP solutions (APplus) tailored to the needs of people with type 2 diabetes (T2D). APplus comprises a product and service package complementing the AP system by obligatory training as well as home visits and telemedical consultations on demand. Outcome predictors and performance indicators shall help to identify people who could benefit most from AP usage and facilitate the measurement of AP impact in diabetes care. In a first step CLOSE will establish a scalable APplus model case working at the interface between patients, homecare service providers, and payers in France. CLOSE will then scale up APplus by pursuing geographic distribution, targeting additional audiences, and enhancing AP functionalities and interconnectedness. By being part of the European Institute of Innovation and Technology (EIT) Health public-private partnership, CLOSE is committed to the EIT "knowledge triangle" pursuing the integrated advancement of technology, education, and business creation. Putting stakeholders, education, and impact into the center of APplus advancement is considered key for achieving wide AP use in T2D care.
在过去十年中,用于1型糖尿病(T1D)患者的人工胰腺(AP)系统取得了巨大进展。泛欧联盟CLOSE(慢性病患者家庭自动血糖控制)旨在开发适合2型糖尿病(T2D)患者需求的集成AP解决方案(APplus)。APplus包括一个产品和服务包,通过强制性培训以及按需进行的家访和远程医疗咨询来补充AP系统。结果预测指标和性能指标应有助于识别最能从使用AP中受益的人群,并便于衡量AP在糖尿病护理中的影响。第一步,CLOSE将在法国建立一个可扩展的APplus模型案例,该案例在患者、家庭护理服务提供商和付款人之间的界面上运行。然后,CLOSE将通过扩大地理分布、针对更多受众以及增强AP功能和互联性来扩大APplus的规模。作为欧洲创新与技术研究所(EIT)健康公私合作伙伴关系的一部分,CLOSE致力于EIT的“知识三角”,追求技术、教育和商业创造的综合进步。将利益相关者、教育和影响置于APplus发展的中心被认为是在T2D护理中广泛使用AP的关键。